ClinicalTrials.gg
CompletedNCT04583618Updated Sep 8, 2025Results posted

Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years.

A Phase 2 interventional study of Pneumococcal Conjugate Vaccine - formulation 1-SP0202-IIb and Pneumococcal Conjugate Vaccine - formulation 2-SP0202-VI in Pneumococcal Immunization, sponsored by Sanofi. Completed at 17 sites in United States. Open to participants aged 50 Years to 84 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-08.

Sponsored by Sanofi · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
750
Allocation
Randomized
Ages
50 Years to 84 Years
Sex
All
01

Study summary

Primary Objectives:

  • Assessed the immune response of the 3 SP0202 formulations, Prevnar 13 and Pneumovax 23 30 days after the administration of the single dose vaccination
  • Assessed the safety profile of the 3 SP0202 formulations, Prevnar 13 and Pneumovax 23
Read the detailed description

The duration of each participant's participation was approximately 6 months.

02

Conditions studied

  • Pneumococcal Immunization
03

In context

Lead sponsor

Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Aged 50 to 84 years on the day of inclusion .

Exclusion criteria

Exclusion criteria:

  • Participant was pregnant, or lactating, or of and was not using an effective method of or abstinence from at least 4 weeks prior to vaccination until at least 4 weeks after vaccination. To be considered of non-childbearing potential, the female must have been for at least 1 year, or surgically sterile.
  • Participation at the time of the study enrollment (or in the 4 weeks preceding the trial vaccination) or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device or medical procedure.
  • Received any vaccine in the 4 weeks preceding the trial vaccination or planned receipt of any vaccine from enrollment through the last blood sampling Visit, except for influenza vaccination, which may be received at least 2 weeks before study vaccine. This exception includes monovalent pandemic influenza vaccines and multivalent influenza vaccines.
  • Previous vaccination against S. pneumoniae with either a pneumococcal conjugated vaccine (PCV) or a pneumococcal polysaccharide vaccine (PPSV).
  • Received immune globulins, blood or blood-derived products in the past 3 months.
  • Known or suspected congenital or acquired immunodeficiency, or receipt of therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
  • History of S. pneumoniae infection or disease, confirmed either serologically, or microbiologically.
  • History of Guillain-Barré syndrome occurring within 6 weeks after a prior dose of a TTxd-containing vaccine.
  • Experienced an Arthus-type reaction following a prior dose of a TTxd-containing vaccine \< 10 years ago.
  • Known systemic hypersensitivity to any of the vaccine components, or history of a life threatening reaction to the vaccines used in the trial or to a vaccine containing any of the same substances .
  • Verbal report of thrombocytopenia contraindicating IM vaccination in the Investigator's opinion.
  • Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM vaccination in the Investigator's opinion.
  • At risk of invasive pneumococcal disease (eg, participants with functional or anatomic asplenia, participants with severe asthma, participants travelling to countries with high endemicity).
  • Current alcohol abuse or drug addiction.
  • Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with trial conduct or completion.
  • Any condition that in the opinion of the Investigator could interfere with the evaluation of the vaccine (eg, under investigation or monitoring for possible coronavirus disease 2019 [COVID-19]).
  • Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature ≥ 100.4 F). A prospective participant should not be included in the study until the condition has resolved or until 3 days after the febrile event has subsided.
  • Received oral or injectable antibiotic therapy within 72 hours prior to the first blood draw.
  • Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (ie, parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
750 participants (actual)

Study arms

  • Experimental
    SP0202-IIb

    One dose at Day 1

    Biological: Pneumococcal Conjugate Vaccine - formulation 1-SP0202-IIb

  • Experimental
    SP0202-VI

    One dose at Day 1

    Biological: Pneumococcal Conjugate Vaccine - formulation 2-SP0202-VI

  • Experimental
    SP0202-VII

    One dose at Day 1

    Biological: Pneumococcal Conjugate Vaccine - formulation 3-SP0202-VII

  • Active comparator
    Prevnar 13

    One dose at Day 1

    Biological: Pneumococcal 13 - valent conjugate vaccine-Prevnar 13

  • Active comparator
    Pneumovax 23

    One dose at Day 1

    Biological: Pneumococcal Vaccine Polyvalent-Pneumovax 23

Interventions

  • BiologicalPneumococcal Conjugate Vaccine - formulation 1-SP0202-IIb

    Pharmaceutical form:Suspension for injection Route of administration: intramuscular

  • BiologicalPneumococcal Conjugate Vaccine - formulation 2-SP0202-VI

    Pharmaceutical form:Suspension for injection Route of administration: intramuscular

  • BiologicalPneumococcal Conjugate Vaccine - formulation 3-SP0202-VII

    Pharmaceutical form:Suspension for injection Route of administration: intramuscular

  • BiologicalPneumococcal 13 - valent conjugate vaccine-Prevnar 13

    Pharmaceutical form:Suspension for injection Route of administration: intramuscular

  • BiologicalPneumococcal Vaccine Polyvalent-Pneumovax 23

    Pharmaceutical form:Solution for injection Route of administration: intramuscular

06

What researchers measure

Primary outcomes

  1. Geometric Mean Titers (GMTs) of Pneumococcal Serotypes Using Serotype-Specific MOPA

    The GMs for serotype specific OPA titers were measured using MOPA which was used to evaluate the opsonophagocytic index (50% killing) of pneumococcal anti-capsular polysaccharide antibodies in human serum samples following vaccination. Titers were expressed in terms of 1/dilution.

    Time frame: Post-vaccination at Day 31

  2. Geometric Mean Titers Ratio of Pneumococcal Serotypes Using Serotype-Specific MOPA

    The GMs for serotype specific OPA titers were measured using MOPA which was used to evaluate the opsonophagocytic index (50% killing) of pneumococcal anti-capsular polysaccharide antibodies in human serum samples following vaccination. Ratio was calculated as post-vaccination titer at Day 31 to pre-vaccination titer at Day 1.

    Time frame: Pre-vaccination at Baseline (Day 1) and Post-vaccination at Day 31

  3. Geometric Mean Concentrations (GMCs) of Pneumococcal Serotypes Using Serotype-Specific IgG ECL

    The GMCs for serotype specific pneumococcal IgG antibodies were measured using ECL, a multiplexed serological assay which allowed for the simultaneous quantification of human IgG against pneumococcal polysaccharide antigens.

    Time frame: Post-vaccination at Day 31

  4. Geometric Mean Concentrations Ratio of Pneumococcal Serotypes Using Serotype-Specific IgG ECL

    The GMCs for serotype specific pneumococcal IgG antibodies were measured using ECL, a multiplexed serological assay which allowed for the simultaneous quantification of human IgG against pneumococcal polysaccharide antigens. Ratio was calculated as post-vaccination titer at Day 31 to pre-vaccination titer at Day 1.

    Time frame: Pre-vaccination at Baseline (Day 1) and Post-vaccination at Day 31

  5. Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs)

    An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, i.e., pre-listed in the CRF in terms of diagnosis and/or onset window post-vaccination. Systemic AEs were all AEs that were not injection or administration site reactions.

    Time frame: Within 30 minutes post-vaccination

  6. Number of Participants With Solicited Injection Site Reactions

    A solicited reaction was an "expected" adverse reaction (AR) (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF. An injection site reaction was an AR at and around the injection site. Solicited injection site reactions included injection site pain, injection site erythema and injection site swelling.

    Time frame: Up to 7 Days post-vaccination (Day 8)

  7. Number of Participants With Solicited Systemic Reactions

    A solicited reaction was an "expected" AR (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF. Solicited systemic reactions included fever, headache, malaise, myalgia, arthralgia and shivering.

    Time frame: Up to 7 Days post-vaccination (Day 8)

  8. Number of Participants With Unsolicited AEs

    An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, i.e., pre-listed in the CRF in terms of diagnosis and/or onset window post-vaccination.

    Time frame: Within 30 days post-vaccination

  9. Number of Participants With Serious Adverse Events (SAEs) and Adverse Event of Special Interest (AESIs)

    An SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. An AESI was defined as one of scientific and medical concern specific to the Sponsor's study intervention or program, for which ongoing monitoring and rapid communication by the investigator to the Sponsor could be appropriate. AESI included analyphylaxis.

    Time frame: From the study vaccine administration (Day 1) until the end of 6-Month follow-up, 181 days

07

Results

Posted Aug 27, 2024

Participant flow

This study was conducted at 17 investigational sites in United States between 08 Oct 2020 to 20 Jan 2022.

Participant flow — Overall Study
MilestoneGroup 1: SP0202-IIbGroup 2: SP0202-VIGroup 3: SP0202-VIIGroup 4: Prevnar 13Group 5: Pneumovax 23
Started151151149149150
Safety analysis set (safas) population151151148149150
Completed148148141147148
Not completed33822
Withdrew: Adverse event00100
Withdrew: Protocol deviation11100
Withdrew: Withdrawal by subject21311
Withdrew: Lost to follow-up01311

Outcome measures

PrimaryGeometric Mean Titers (GMTs) of Pneumococcal Serotypes Using Serotype-Specific MOPA

The GMs for serotype specific OPA titers were measured using MOPA which was used to evaluate the opsonophagocytic index (50% killing) of pneumococcal anti-capsular polysaccharide antibodies in human serum samples following vaccination. Titers were expressed in terms of 1/dilution.

Time frame:
Post-vaccination at Day 31
Reported as:
Geometric mean · Titer
Geometric Mean Titers (GMTs) of Pneumococcal Serotypes Using Serotype-Specific MOPA
TiterGroup 1: SP0202-IIbGroup 2: SP0202-VIGroup 3: SP0202-VIIGroup 4: Prevnar 13Group 5: Pneumovax 23
Serotype 1128 (92.5 to 177)127 (90.3 to 178)158 (113 to 220)254 (183 to 353)289 (213 to 392)
Serotype 3136 (109 to 170)217 (176 to 269)263 (214 to 323)157 (126 to 196)177 (142 to 221)
Serotype 41494 (1175 to 1900)1306 (1029 to 1658)2134 (1675 to 2719)2941 (2360 to 3664)1873 (1415 to 2480)
Serotype 5241 (166 to 349)230 (160 to 330)201 (143 to 281)536 (378 to 760)377 (272 to 523)
Serotype 6A2931 (2143 to 4010)3074 (2389 to 3957)2672 (1923 to 3714)3350 (2418 to 4641)443 (288 to 681)
Serotype 6B3699 (2857 to 4788)3582 (2763 to 4645)3479 (2595 to 4664)5122 (3916 to 6699)2153 (1561 to 2969)
Serotype 7F3487 (2811 to 4326)2841 (2262 to 3568)2403 (1878 to 3074)4253 (3309 to 5466)2250 (1721 to 2943)
Serotype 9V826 (607 to 1123)828 (614 to 1117)986 (700 to 1388)1641 (1274 to 2114)1159 (863 to 1556)
Serotype 143756 (2995 to 4709)4407 (3385 to 5737)3244 (2421 to 4349)3675 (2904 to 4650)3999 (3099 to 5161)
Serotype 18C905 (676 to 1210)802 (590 to 1090)1025 (756 to 1390)1929 (1460 to 2548)1177 (875 to 1585)
Serotype 19A2067 (1719 to 2485)3395 (2796 to 4123)3462 (2771 to 4324)4417 (3537 to 5515)2261 (1841 to 2776)
Serotype 19F897 (702 to 1145)1773 (1406 to 2236)1678 (1336 to 2108)1525 (1165 to 1997)983 (742 to 1303)
Serotype 23F1999 (1478 to 2704)1576 (1153 to 2153)1701 (1284 to 2255)1792 (1311 to 2450)488 (319 to 747)
Serotype 81363 (1110 to 1674)1377 (1129 to 1680)1486 (1207 to 1829)74.8 (52.3 to 107)2039 (1664 to 2499)
Serotype 9N3656 (2988 to 4474)3858 (3145 to 4733)4207 (3430 to 5160)1082 (806 to 1453)6096 (4837 to 7682)
Serotype 10A3501 (2689 to 4557)2856 (2190 to 3724)2811 (2047 to 3860)104 (64.3 to 167)3011 (2060 to 4399)
Serotype 11A475 (354 to 637)438 (324 to 594)318 (226 to 448)18.3 (13.0 to 25.6)390 (285 to 534)
Serotype 12F3492 (2587 to 4714)3917 (3116 to 4925)3117 (2311 to 4203)8.31 (6.19 to 11.2)1345 (914 to 1980)
Serotype 15B4930 (3641 to 6677)4823 (3588 to 6484)3613 (2541 to 5138)160 (112 to 230)3346 (2409 to 4648)
Serotype 22F5253 (4147 to 6653)4639 (3587 to 6001)4858 (3683 to 6406)62.5 (42.4 to 92.1)1906 (1456 to 2495)
Serotype 33F7313 (5890 to 9078)8324 (6488 to 10680)7641 (6205 to 9410)1201 (898 to 1605)15082 (11551 to 19692)
PrimaryGeometric Mean Titers Ratio of Pneumococcal Serotypes Using Serotype-Specific MOPA

The GMs for serotype specific OPA titers were measured using MOPA which was used to evaluate the opsonophagocytic index (50% killing) of pneumococcal anti-capsular polysaccharide antibodies in human serum samples following vaccination. Ratio was calculated as post-vaccination titer at Day 31 to pre-vaccination titer at Day 1.

Time frame:
Pre-vaccination at Baseline (Day 1) and Post-vaccination at Day 31
Reported as:
Geometric mean · Ratio
Geometric Mean Titers Ratio of Pneumococcal Serotypes Using Serotype-Specific MOPA
RatioGroup 1: SP0202-IIbGroup 2: SP0202-VIGroup 3: SP0202-VIIGroup 4: Prevnar 13Group 5: Pneumovax 23
Serotype 18.40 (6.28 to 11.2)10.5 (7.95 to 14.0)9.79 (7.15 to 13.4)21.3 (15.6 to 29.0)19.1 (14.4 to 25.3)
Serotype 37.06 (5.55 to 8.99)12.9 (10.1 to 16.4)13.7 (10.7 to 17.4)8.52 (6.71 to 10.8)9.52 (7.56 to 12.0)
Serotype 420.7 (14.7 to 29.3)28.8 (20.6 to 40.3)33.0 (22.2 to 49.2)58.9 (41.2 to 84.1)25.7 (18.2 to 36.4)
Serotype 515.2 (11.0 to 21.0)19.5 (14.3 to 26.7)12.2 (9.10 to 16.4)37.4 (26.9 to 52.1)24.2 (18.2 to 32.2)
Serotype 6A60.8 (42.8 to 86.5)69.4 (48.3 to 99.8)59.2 (40.9 to 85.8)79.1 (54.4 to 115)9.18 (6.34 to 13.3)
Serotype 6B29.1 (20.6 to 41.2)25.7 (18.1 to 36.6)29.2 (19.5 to 43.6)49.3 (34.8 to 69.7)16.6 (11.5 to 23.8)
Serotype 7F50.8 (32.8 to 78.9)49.0 (32.5 to 73.7)24.0 (14.9 to 38.7)79.1 (51.6 to 121)31.0 (21.0 to 45.8)
Serotype 9V9.50 (7.01 to 12.9)9.90 (7.20 to 13.6)12.7 (8.90 to 18.0)17.2 (12.2 to 24.1)10.6 (7.78 to 14.4)
Serotype 147.44 (5.25 to 10.5)14.3 (9.69 to 21.0)8.44 (5.68 to 12.5)10.1 (7.03 to 14.6)9.05 (6.46 to 12.7)
Serotype 18C17.0 (12.4 to 23.3)20.6 (15.0 to 28.2)18.9 (13.3 to 27.0)43.1 (31.1 to 59.8)22.1 (16.3 to 30.0)
Serotype 19A7.36 (5.77 to 9.38)13.1 (10.3 to 16.8)11.5 (8.66 to 15.3)15.5 (11.4 to 21.0)7.88 (6.26 to 9.91)
Serotype 19F13.1 (9.45 to 18.2)30.7 (21.9 to 43.0)20.8 (15.0 to 29.0)26.6 (19.0 to 37.1)17.2 (12.5 to 23.7)
Serotype 23F45.2 (31.0 to 65.9)43.0 (29.0 to 63.8)43.9 (29.6 to 65.1)45.5 (32.2 to 64.4)11.6 (7.99 to 16.8)
Serotype 818.6 (13.5 to 25.6)24.1 (17.7 to 32.8)24.0 (16.3 to 35.3)1.37 (1.14 to 1.65)37.6 (27.8 to 50.8)
Serotype 9N8.90 (6.29 to 12.6)12.8 (8.90 to 18.4)11.5 (7.88 to 16.8)2.84 (2.12 to 3.79)14.6 (10.7 to 20.0)
Serotype 10A24.2 (16.3 to 35.8)24.7 (16.5 to 36.9)20.8 (13.4 to 32.3)1.05 (0.932 to 1.19)22.9 (16.1 to 32.7)
Serotype 11A14.8 (10.4 to 21.0)15.9 (11.1 to 22.6)9.28 (6.46 to 13.3)0.964 (0.786 to 1.18)13.7 (9.64 to 19.5)
Serotype 12F240 (163 to 354)252 (181 to 353)167 (106 to 263)0.975 (0.870 to 1.09)102 (67.7 to 153)
Serotype 15B30.1 (20.8 to 43.6)34.3 (23.3 to 50.5)20.7 (14.1 to 30.4)1.21 (0.997 to 1.47)22.8 (16.1 to 32.1)
Serotype 22F39.0 (27.2 to 56.1)41.4 (28.5 to 60.3)38.5 (25.4 to 58.3)0.878 (0.679 to 1.14)21.0 (15.1 to 29.1)
Serotype 33F4.21 (3.27 to 5.41)6.27 (4.72 to 8.32)4.36 (3.45 to 5.52)0.931 (0.871 to 0.995)10.4 (7.76 to 13.9)
PrimaryGeometric Mean Concentrations (GMCs) of Pneumococcal Serotypes Using Serotype-Specific IgG ECL

The GMCs for serotype specific pneumococcal IgG antibodies were measured using ECL, a multiplexed serological assay which allowed for the simultaneous quantification of human IgG against pneumococcal polysaccharide antigens.

Time frame:
Post-vaccination at Day 31
Reported as:
Geometric mean · mcg/mL
Geometric Mean Concentrations (GMCs) of Pneumococcal Serotypes Using Serotype-Specific IgG ECL
mcg/mLGroup 1: SP0202-IIbGroup 2: SP0202-VIGroup 3: SP0202-VIIGroup 4: Prevnar 13Group 5: Pneumovax 23
Serotype 12.98 (2.29 to 3.88)3.28 (2.59 to 4.17)4.17 (3.29 to 5.28)5.93 (4.49 to 7.85)7.43 (5.75 to 9.60)
Serotype 30.746 (0.616 to 0.903)0.977 (0.818 to 1.17)1.22 (1.01 to 1.49)0.899 (0.738 to 1.10)0.858 (0.717 to 1.03)
Serotype 41.97 (1.60 to 2.43)1.63 (1.32 to 2.00)2.27 (1.81 to 2.84)3.28 (2.61 to 4.12)1.72 (1.38 to 2.13)
Serotype 52.35 (1.78 to 3.10)2.16 (1.62 to 2.87)2.16 (1.68 to 2.78)4.34 (3.20 to 5.90)3.98 (3.09 to 5.12)
Serotype 6A6.04 (4.45 to 8.22)5.00 (3.83 to 6.54)4.83 (3.57 to 6.54)7.89 (5.90 to 10.5)1.53 (1.16 to 2.02)
Serotype 6B5.73 (4.17 to 7.89)3.62 (2.66 to 4.93)4.37 (3.22 to 5.95)6.45 (4.92 to 8.45)2.47 (1.86 to 3.28)
Serotype 7F6.56 (5.23 to 8.22)5.56 (4.58 to 6.75)5.35 (4.30 to 6.65)10.1 (8.01 to 12.6)4.23 (3.34 to 5.35)
Serotype 9V2.91 (2.29 to 3.72)3.17 (2.52 to 4.00)4.31 (3.43 to 5.41)5.30 (4.20 to 6.68)3.48 (2.75 to 4.41)
Serotype 1412.4 (9.88 to 15.7)10.5 (8.21 to 13.6)9.52 (7.34 to 12.3)10.5 (8.22 to 13.4)14.6 (11.2 to 19.0)
Serotype 18C5.50 (4.44 to 6.82)5.39 (4.39 to 6.62)5.41 (4.44 to 6.59)10.3 (8.15 to 13.1)5.44 (4.34 to 6.81)
Serotype 19A7.41 (6.03 to 9.10)11.7 (9.16 to 15.1)10.9 (8.41 to 14.2)18.3 (14.4 to 23.2)7.59 (6.05 to 9.52)
Serotype 19F3.77 (2.92 to 4.87)8.35 (6.22 to 11.2)7.03 (5.30 to 9.33)9.38 (7.16 to 12.3)4.47 (3.40 to 5.88)
Serotype 23F7.35 (5.56 to 9.72)5.52 (4.26 to 7.13)6.59 (5.05 to 8.61)6.99 (5.33 to 9.17)3.02 (2.31 to 3.96)
Serotype 87.14 (5.75 to 8.87)6.25 (5.09 to 7.68)6.23 (4.98 to 7.80)0.935 (0.703 to 1.24)9.84 (8.14 to 11.9)
Serotype 9N5.26 (4.06 to 6.81)4.50 (3.55 to 5.71)6.54 (5.09 to 8.40)1.60 (1.20 to 2.12)6.41 (5.10 to 8.06)
Serotype 10A7.16 (5.37 to 9.55)9.48 (7.10 to 12.6)7.37 (5.39 to 10.1)1.06 (0.840 to 1.35)9.11 (6.83 to 12.1)
Serotype 11A4.85 (3.99 to 5.89)4.91 (4.08 to 5.89)4.27 (3.51 to 5.20)0.884 (0.745 to 1.05)3.88 (3.19 to 4.72)
Serotype 12F2.18 (1.58 to 3.02)2.09 (1.55 to 2.83)1.90 (1.41 to 2.55)0.190 (0.158 to 0.228)1.03 (0.780 to 1.36)
Serotype 15B13.4 (10.5 to 17.2)16.3 (12.8 to 20.8)14.8 (11.7 to 18.8)1.84 (1.42 to 2.39)13.6 (10.8 to 17.2)
Serotype 22F3.57 (2.88 to 4.44)4.02 (3.20 to 5.05)3.78 (3.03 to 4.71)0.350 (0.283 to 0.433)2.41 (1.93 to 3.00)
Serotype 33F7.98 (6.19 to 10.3)9.15 (7.42 to 11.3)7.75 (6.18 to 9.72)1.50 (1.21 to 1.85)16.4 (12.8 to 21.1)
PrimaryGeometric Mean Concentrations Ratio of Pneumococcal Serotypes Using Serotype-Specific IgG ECL

The GMCs for serotype specific pneumococcal IgG antibodies were measured using ECL, a multiplexed serological assay which allowed for the simultaneous quantification of human IgG against pneumococcal polysaccharide antigens. Ratio was calculated as post-vaccination titer at Day 31 to pre-vaccination titer at Day 1.

Time frame:
Pre-vaccination at Baseline (Day 1) and Post-vaccination at Day 31
Reported as:
Geometric mean · Ratio
Geometric Mean Concentrations Ratio of Pneumococcal Serotypes Using Serotype-Specific IgG ECL
RatioGroup 1: SP0202-IIbGroup 2: SP0202-VIGroup 3: SP0202-VIIGroup 4: Prevnar 13Group 5: Pneumovax 23
Serotype 15.39 (4.33 to 6.70)6.47 (5.27 to 7.95)6.41 (5.11 to 8.03)11.6 (9.21 to 14.6)11.5 (9.09 to 14.5)
Serotype 32.99 (2.49 to 3.61)4.02 (3.40 to 4.76)4.93 (4.07 to 5.97)3.86 (3.21 to 4.65)3.52 (3.01 to 4.12)
Serotype 46.52 (5.32 to 7.98)5.91 (4.93 to 7.07)7.33 (5.90 to 9.10)10.8 (8.71 to 13.3)5.47 (4.57 to 6.55)
Serotype 55.43 (4.32 to 6.82)5.81 (4.67 to 7.22)4.60 (3.75 to 5.66)10.6 (8.15 to 13.7)8.93 (7.15 to 11.1)
Serotype 6A13.8 (10.5 to 18.2)12.2 (9.79 to 15.3)12.6 (9.76 to 16.4)19.3 (14.9 to 24.9)3.30 (2.75 to 3.96)
Serotype 6B12.2 (9.31 to 16.0)9.63 (7.59 to 12.2)10.7 (8.10 to 14.0)16.2 (12.8 to 20.5)5.51 (4.51 to 6.74)
Serotype 7F10.6 (8.37 to 13.4)9.67 (7.86 to 11.9)7.93 (6.30 to 9.99)16.3 (12.8 to 20.7)6.80 (5.67 to 8.16)
Serotype 9V5.65 (4.59 to 6.95)6.29 (5.09 to 7.76)7.87 (6.28 to 9.86)9.12 (7.53 to 11.0)6.30 (5.17 to 7.68)
Serotype 144.91 (3.93 to 6.13)6.44 (5.06 to 8.19)4.62 (3.59 to 5.95)5.96 (4.68 to 7.58)7.35 (5.85 to 9.23)
Serotype 18C6.52 (5.26 to 8.08)7.18 (5.86 to 8.79)6.21 (5.09 to 7.58)12.1 (9.52 to 15.3)6.91 (5.74 to 8.31)
Serotype 19A4.74 (3.89 to 5.78)8.76 (7.14 to 10.7)7.86 (6.28 to 9.84)12.3 (9.79 to 15.4)5.74 (4.72 to 6.98)
Serotype 19F4.97 (4.02 to 6.15)11.2 (8.82 to 14.3)9.65 (7.53 to 12.4)11.2 (8.77 to 14.2)6.18 (5.07 to 7.53)
Serotype 23F13.2 (10.2 to 17.2)11.0 (8.75 to 13.9)11.9 (9.21 to 15.3)13.0 (10.3 to 16.4)5.70 (4.57 to 7.12)
Serotype 87.97 (6.41 to 9.92)8.44 (6.88 to 10.3)8.20 (6.54 to 10.3)1.26 (1.11 to 1.42)13.9 (11.5 to 16.8)
Serotype 9N6.52 (5.22 to 8.14)8.39 (6.67 to 10.5)9.99 (7.87 to 12.7)2.81 (2.36 to 3.35)11.3 (9.20 to 13.8)
Serotype 10A8.45 (6.74 to 10.6)10.0 (8.01 to 12.6)7.55 (5.83 to 9.78)1.15 (1.07 to 1.22)9.84 (7.98 to 12.1)
Serotype 11A5.57 (4.56 to 6.82)6.13 (5.08 to 7.38)5.36 (4.36 to 6.61)1.18 (1.10 to 1.27)5.54 (4.65 to 6.60)
Serotype 12F8.70 (6.66 to 11.4)9.47 (7.29 to 12.3)8.05 (6.20 to 10.5)1.08 (1.02 to 1.14)5.07 (4.01 to 6.40)
Serotype 15B7.77 (6.28 to 9.63)11.6 (9.13 to 14.7)8.74 (6.99 to 10.9)1.35 (1.19 to 1.52)9.87 (7.95 to 12.2)
Serotype 22F9.21 (7.38 to 11.5)10.0 (8.09 to 12.5)8.99 (7.32 to 11.0)1.09 (1.02 to 1.17)7.30 (5.95 to 8.95)
Serotype 33F4.54 (3.68 to 5.60)5.59 (4.58 to 6.81)4.43 (3.60 to 5.45)1.03 (0.981 to 1.08)9.43 (7.64 to 11.6)
PrimaryNumber of Participants With Immediate Unsolicited Systemic Adverse Events (AEs)

An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, i.e., pre-listed in the CRF in terms of diagnosis and/or onset window post-vaccination. Systemic AEs were all AEs that were not injection or administration site reactions.

Time frame:
Within 30 minutes post-vaccination
Reported as:
Count of participants · Participants
Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs)
ParticipantsGroup 1: SP0202-IIbGroup 2: SP0202-VIGroup 3: SP0202-VIIGroup 4: Prevnar 13Group 5: Pneumovax 23
Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs)00100
PrimaryNumber of Participants With Solicited Injection Site Reactions

A solicited reaction was an "expected" adverse reaction (AR) (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF. An injection site reaction was an AR at and around the injection site. Solicited injection site reactions included injection site pain, injection site erythema and injection site swelling.

Time frame:
Up to 7 Days post-vaccination (Day 8)
Reported as:
Count of participants · Participants
Number of Participants With Solicited Injection Site Reactions
ParticipantsGroup 1: SP0202-IIbGroup 2: SP0202-VIGroup 3: SP0202-VIIGroup 4: Prevnar 13Group 5: Pneumovax 23
Injection site pain1061131078574
Injection site erythema17251939
Injection site swelling14191446
PrimaryNumber of Participants With Solicited Systemic Reactions

A solicited reaction was an "expected" AR (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF. Solicited systemic reactions included fever, headache, malaise, myalgia, arthralgia and shivering.

Time frame:
Up to 7 Days post-vaccination (Day 8)
Reported as:
Count of participants · Participants
Number of Participants With Solicited Systemic Reactions
ParticipantsGroup 1: SP0202-IIbGroup 2: SP0202-VIGroup 3: SP0202-VIIGroup 4: Prevnar 13Group 5: Pneumovax 23
Fever32534
Headache4347383541
Malaise3643302832
Myalgia5771564965
Arthralgia2330181729
Shivering202718713
PrimaryNumber of Participants With Unsolicited AEs

An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, i.e., pre-listed in the CRF in terms of diagnosis and/or onset window post-vaccination.

Time frame:
Within 30 days post-vaccination
Reported as:
Count of participants · Participants
Number of Participants With Unsolicited AEs
ParticipantsGroup 1: SP0202-IIbGroup 2: SP0202-VIGroup 3: SP0202-VIIGroup 4: Prevnar 13Group 5: Pneumovax 23
Number of Participants With Unsolicited AEs2134191820
PrimaryNumber of Participants With Serious Adverse Events (SAEs) and Adverse Event of Special Interest (AESIs)

An SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. An AESI was defined as one of scientific and medical concern specific to the Sponsor's study intervention or program, for which ongoing monitoring and rapid communication by the investigator to the Sponsor could be appropriate. AESI included analyphylaxis.

Time frame:
From the study vaccine administration (Day 1) until the end of 6-Month follow-up, 181 days
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs) and Adverse Event of Special Interest (AESIs)
ParticipantsGroup 1: SP0202-IIbGroup 2: SP0202-VIGroup 3: SP0202-VIIGroup 4: Prevnar 13Group 5: Pneumovax 23
SAEs37322
AESIs00000

Adverse events

Collected over AEs, SAEs and all-cause mortality (deaths) were collected from the study vaccine administration (Day 1) until the end of 6-Month follow-up, 181 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: SP0202-IIb0/151 (0%)3/151 (2%)113/151 (74.8%)
Group 2: SP0202-VI1/151 (0.7%)7/151 (4.6%)122/151 (80.8%)
Group 3: SP0202-VII1/148 (0.7%)3/148 (2%)112/148 (75.7%)
Group 4: Prevnar 130/149 (0%)2/149 (1.3%)102/149 (68.5%)
Group 5: Pneumovax 230/150 (0%)2/150 (1.3%)93/150 (62%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventGroup 1: SP0202-IIbGroup 2: SP0202-VIGroup 3: SP0202-VIIGroup 4: Prevnar 13Group 5: Pneumovax 23
Atrial FibrillationCardiac disorders0/1511/1511/1480/1490/150
Covid-19 PneumoniaInfections and infestations1/1511/1511/1480/1490/150
Subdural HaematomaInjury, poisoning and procedural complications0/1510/1511/1480/1490/150
Acute Respiratory FailureRespiratory, thoracic and mediastinal disorders0/1510/1511/1480/1490/150
Acute Myocardial InfarctionCardiac disorders0/1510/1510/1481/1490/150
Small Intestinal ObstructionGastrointestinal disorders0/1510/1510/1481/1490/150
PneumoniaInfections and infestations0/1510/1510/1481/1490/150
Pneumonia AspirationInfections and infestations0/1510/1510/1481/1490/150
DiverticulitisInfections and infestations0/1510/1510/1480/1491/150
Cerebral HaemorrhageNervous system disorders0/1510/1510/1480/1491/150
Most frequent other events
Most frequent other events
EventGroup 1: SP0202-IIbGroup 2: SP0202-VIGroup 3: SP0202-VIIGroup 4: Prevnar 13Group 5: Pneumovax 23
Injection Site PainGeneral disorders106/151113/151107/14885/14974/150
MyalgiaMusculoskeletal and connective tissue disorders57/15172/15156/14849/14965/150
HeadacheNervous system disorders43/15148/15138/14836/14942/150
MalaiseGeneral disorders36/15143/15130/14828/14932/150
ArthralgiaMusculoskeletal and connective tissue disorders23/15130/15118/14817/14931/150
ChillsGeneral disorders20/15127/15118/1487/14913/150
Injection Site ErythemaGeneral disorders17/15125/15120/1484/1499/150
Injection Site SwellingGeneral disorders14/15119/15114/1484/1496/150

Baseline characteristics

Randomized population included all participants with data in the case report form (CRF).

Age, Continuous
Age, Continuous(Years)Group 1: SP0202-IIbGroup 2: SP0202-VIGroup 3: SP0202-VIIGroup 4: Prevnar 13Group 5: Pneumovax 23Total
Mean63.3 ± 6.963.1 ± 6.662.9 ± 6.563.4 ± 6.863.1 ± 7.263.2 ± 6.8
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: SP0202-IIbGroup 2: SP0202-VIGroup 3: SP0202-VIIGroup 4: Prevnar 13Group 5: Pneumovax 23Total
Female7684788693417
Male7567716357333
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Group 1: SP0202-IIbGroup 2: SP0202-VIGroup 3: SP0202-VIIGroup 4: Prevnar 13Group 5: Pneumovax 23Total
American Indian or Alaska Native102104
Black or African American191724101383
Native Hawaiian or other Pacific Islander010102
White120123113127121604
Asian1099101149
Multiple100012
Not reported011046
08

Study locations

17 sites
  • Emmaus Research Center, Inc Site Number : 8400014
    Anaheim, California 92804, United States
  • Peninsula Research Associates Site Number : 8400012
    Rolling Hills Estates, California 90274, United States
  • Paradigm Clinical Research Center Wheat Ridge Site Number : 8400002
    Wheat Ridge, Colorado 80033, United States
  • Jacksonville Center for Clinical Research Site Number : 8400016
    Jacksonville, Florida 32216, United States
  • Suncoast Research Associates, LLC Site Number : 8400017
    Miami, Florida 33173, United States
  • Advanced Clinical Research - Magic View Site Number : 8400003
    Meridian, Idaho 83642, United States
  • Velocity Clinical Research Valparaiso Site Number : 8400001
    Valparaiso, Indiana 46383, United States
  • Velocity Clinical Research Site Number : 8400005
    Metairie, Louisiana 70006, United States
  • Be Well Clinical Studies Site Number : 8400018
    Lincoln, Nebraska 68516, United States
  • WR-CRCN, LLC Site Number : 8400013
    Las Vegas, Nevada 89106, United States
  • Biotrial Inc Site Number : 8400006
    Newark, New Jersey 07103, United States
  • Plains Clinical Research Center, LLC Site Number : 8400011
    Fargo, North Dakota 58104, United States
  • Aventiv Research Columbus Site Number : 8400007
    Columbus, Ohio 43213, United States
  • Velocity Clinical Research, Medford Site Number : 8400010
    Medford, Oregon 97504, United States
  • Preferred Primary Care Physicians Site Number : 8400009
    Pittsburgh, Pennsylvania 15236, United States
  • Coastal Carolina Research Center - N Charleston Site Number : 8400004
    North Charleston, South Carolina 29405, United States
  • JBR Clinical Research Site Number : 8400008
    Salt Lake City, Utah 84107, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in Aug 2021, 10 months.

Results were first posted in Aug 2024, 3 years after primary completion. A results delay was requested in Aug 2022.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2020
First posted
Oct 12, 2020
StartActual
Oct 8, 2020
Primary completionActual
Aug 9, 2021
CompletionActual
Jan 20, 2022
Results delay requested
Aug 1, 2022
Results first posted
Aug 27, 2024
Last update
Sep 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04583618
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Oct 12, 2020
Start date
Oct 8, 2020
Primary completion
Aug 9, 2021
Completion
Jan 20, 2022
Results posted
Aug 27, 2024
Last update
Sep 8, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion